Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 4/2024

Open Access 14-02-2024 | Positron Emission Tomography | Original Article

Methyl-11C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma

Authors: Hikaru Niitsu, Nobuyoshi Fukumitsu, Keiichi Tanaka, Masashi Mizumoto, Kei Nakai, Masahide Matsuda, Eiichi Ishikawa, Kentaro Hatano, Tsuyoshi Hashimoto, Satoshi Kamizawa, Hideyuki Sakurai

Published in: Annals of Nuclear Medicine | Issue 4/2024

Login to get access

Abstract

Objective

To investigate differences in uptake regions between methyl-11C-L-methionine positron emission tomography (11C-MET PET) and gadolinium (Gd)-enhanced magnetic resonance imaging (MRI), and their impact on dose distribution, including changing of the threshold for tumor boundaries.

Methods

Twenty consecutive patients with grade 3 or 4 glioma who had recurrence after postoperative radiotherapy (RT) between April 2016 and October 2017 were examined. The study was performed using simulation with the assumption that all patients received RT. The clinical target volume (CTV) was contoured using the Gd-enhanced region (CTV(Gd)), the tumor/normal tissue (T/N) ratios of 11C-MET PET of 1.3 and 2.0 (CTV (T/N 1.3), CTV (T/N 2.0)), and the PET-edge method (CTV(P-E)) for stereotactic RT planning. Differences among CTVs were evaluated. The brain dose at each CTV and the dose at each CTV defined by 11C-MET PET using MRI as the reference were evaluated.

Results

The Jaccard index (JI) for concordance of CTV (Gd) with CTVs using 11C-MET PET was highest for CTV (T/N 2.0), with a value of 0.7. In a comparison of pixel values of MRI and PET, the correlation coefficient for cases with higher JI was significantly greater than that for lower JI cases (0.37 vs. 0.20, P = 0.007). D50% of the brain in RT planning using each CTV differed significantly (P = 0.03) and that using CTV (T/N 1.3) were higher than with use of CTV (Gd). V90% and V95% for each CTV differed in a simulation study for actual treatment using CTV (Gd) (P = 1.0 × 10–7 and 3.0 × 10–9, respectively) and those using CTV (T/N 1.3) and CTV (P-E) were lower than with CTV (Gd).

Conclusions

The region of 11C-MET accumulation is not necessarily consistent with and larger than the Gd-enhanced region. A change of the tumor boundary using 11C-MET PET can cause significant changes in doses to the brain and the CTV.
Appendix
Available only for authorised users
Literature
1.
Narita Y, Shibui S. Trends and outcomes in the treatment of gliomas based on data during 2001–2004 from the brain tumor registry of Japan. Neurol Med Chir (Tokyo). 2015;55:286–95.
2.
Navarria P, Minniti G, Clerici E, Tomatis S, Pinzi V, Ciammella P, et al. Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the Radiation Oncology Italian Association. J Neurooncol. 2019;142:59–67.
3.
Navarria P, Pessina F, Clerici E, Bellu L, Franzese C, Franzini A, et al. Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. Radiother Oncol. 2022;167:89–96.CrossRefPubMed
4.
Kinoshita M, Goto T, Arita H, Okita Y, Isohashi K, Kagawa N, et al. Imaging 18F-fluorodeoxy glucose/11C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. J Neurooncol. 2012;106:417–25.CrossRefPubMed
5.
Hirata T, Kinoshita M, Tamari K, Seo Y, Suzuki O, Wakai N, et al. 11C-methionine-18F-FDG dual-PET-tracer-based target delineation of malignant glioma: evaluation of its geometrical and clinical features for planning radiation therapy. J Nerusurg. 2019;131:676–86.CrossRef
6.
Whitfield G, Kennedy S, Djoukhadar I, Jackson A. Imaging and target volume delineation in Glioma. Clin Oncol. 2014;26:364–76.CrossRef
7.
Langstrom B, Antoni G, Gullberg P, Halldin C, Malmborg P, Nagren K, et al. Synthesis of L- and D-[methyl-11C] methionine. J Nucl Med. 1987;28:1037–40.PubMed
8.
Iuchi T, Hatano K, Uchino Y, Itami M, Hasegawa Y, Kawasaki K, et al. Methionine uptake and required radiation dose to control glioblastoma. Int J Radiat Oncol Biol Phys. 2015;93:133–40.CrossRefPubMed
9.
Glaudemans A, Enting R, Heesters M, Dierckx R, Rheenen VR, Walenkamp A, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35.CrossRefPubMed
10.
Becherer A, Karanikas G, Szabo M, Zettinig G, Asenbaum S, Marosi C, et al. Brain tumour imaging with PET: a comparison between [18F] fluorodopa and [11C] methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561–7.CrossRefPubMed
11.
Braun V, Dempf S, Weller R, Reske SN, Schachenmayr W, Richter HP, et al. Cranial neuronavigation with direct integration of 11C methionine positron emission tomography (PET) data–results of a pilot study in 32 surgical cases. Acta Neurochir (Wien). 2002;144:777–82.
12.
Chung JK, Kim YK, Kim SK, Lee SK, Lee YJ, Paek S, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176–82.CrossRefPubMed
13.
Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50(5):1316–22.CrossRefPubMed
14.
Ullrich RT, Kracht L, Brunn A, Herholz K, Frommolt P, Miletic H, et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. 2009;50:1962–8.CrossRefPubMed
15.
Yamamoto Y, Nishiyama Y, Kimura N, Kameyama R, Kawai N, Hatakeyama T, et al. 11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET. Mol Imaging Biol. 2008;10:281–7.CrossRefPubMed
16.
Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–58.PubMed
17.
Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11C] methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48:43–52.CrossRefPubMed
18.
Mineura K, Sasajima T, Suda Y, Kowada M, Shishido F, Uemura K, et al. Amino acid study of cerebral gliomas using positron emission tomography–analysis of (11C-methyl)-L-methionine uptake index. Neurol Med Chir (Tokyo). 1990;30:997–1002.CrossRefPubMed
19.
Mosskin M, Bergstrom M, Collins VP, Ehrin E, Eriksson L, Holst H, et al. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol Suppl. 1986;369:157–60.PubMed
20.
Mosskin M, Ericson K, Hindmarsh T, Holst H, Collins VP, Bergstrom M, et al. Positron emission tomography compared with magnetic resonance imaging and computed tomography insupratentorial gliomas using multiple stereotactic biopsies asreference. Acta Radiol. 1989;30:225–32.CrossRefPubMed
21.
Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of brain tumor extent with [11C] L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70.CrossRefPubMed
22.
Kinoshita M, Hashimoto N, Goto T, Yanagisawa T, Okita Y, Kagawa N, et al. Use of fractional anisotropy for determination of the cut-off value in 11C-methionine positron emission tomography for glioma. Neuroimage. 2009;45:312–8.CrossRefPubMed
23.
Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:64–74.CrossRefPubMed
24.
Galldiks N, Dunkl V, Kracht LW, Vollmar S, Jacobs AH, Fink GR, et al. Volumetry of [11C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma. Mol Imaging. 2012;11:516–27.CrossRefPubMed
25.
Jung TY, Min JJ, Bom HS, Bom HS, Jung S, Kim IY, et al. Prognostic value of post-treatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma. Neruosurg Rev. 2017;40:223–9.CrossRef
26.
Cicuendez M, Bosquet CL, Borros GC, Ricarte FM, Cordero E, Saez EM, et al. Role of [11C] methionine positron emission tomography in the diagnosis and prediction of survival in brain tumours. Clin Neurol Nerosurg. 2015;139:328–33.CrossRef
27.
Kano H, Kondziolka D, Lobato-Polo J, Zorro O, Flickinger JC, Lunsford LD, et al. T1/T2 matching to differentiate tumor growth from radiation effects after stereotactic radiosurgery. Neurosurgery. 2010;66:486–91.CrossRefPubMed
28.
Mizumoto M, Okumura T, Ishikawa E, Yamamoto T, Takano S, Matsumura A, et al. Reirradiation for recurrent malignant brain tumor with radiotherapy or proton beam therapy. Strahlenther Onkol. 2013;189:656–63.CrossRefPubMed
29.
Werner-Wasik M, Nelson AD, Choi W, Arai Y, Faulhaber PF, Kang P, et al. What is the best way to contour lung tumors on pet scans? Multiobserever validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys. 2012;82:1164–71.CrossRefPubMed
30.
Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238–53.CrossRefPubMed
31.
Navarria P, Reggiori G, Pessina F, Ascolese AM, Tomatis S, Mancosu P, et al. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiother Oncol. 2014;112:425–9.CrossRefPubMed
32.
Lee IH, Piert M, Hassan DG, Junck L, Rogers L, Hayman J, et al. Association of 11C-Methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:479–85.CrossRefPubMed
33.
Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law L, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients—a report of the PET/RANO group. Neuro Oncol. 2021;23:881–93.CrossRefPubMedPubMedCentral
34.
Grosu A, Weber WA, Franz M, Stark S, Piert M, Thamm R, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET(SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511–9.CrossRefPubMed
35.
Miwa K, Matsuo M, Ogawa S, Shinoda J, Yokoyama K, Yamada J, et al. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation. Radiat Oncol. 2014;9:181.CrossRefPubMedPubMedCentral
36.
Japanese Society for Raiation Oncology (JASTRO). JASTRO guidelines 2020 for radiotherapy treatment planning. Kanehara & Co., Ltd; 2020. pp 70–4.
37.
Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, et al. Radiation therapy for glioblastoma: an ASTRO evidence-based clinical practice. Pract Radiat Oncol. 2016;6(4):217–25.CrossRefPubMed
38.
39.
Leao DJ, Craig PG, Godoy LF, Leite CC, Policeni B. Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques. Am J Neuroradiol. 2020;41:10–20.CrossRefPubMedPubMedCentral
40.
Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199–208.CrossRefPubMedPubMedCentral
Metadata
Title
Methyl-11C-L-methionine positron emission tomography for radiotherapy planning for recurrent malignant glioma
Authors
Hikaru Niitsu
Nobuyoshi Fukumitsu
Keiichi Tanaka
Masashi Mizumoto
Kei Nakai
Masahide Matsuda
Eiichi Ishikawa
Kentaro Hatano
Tsuyoshi Hashimoto
Satoshi Kamizawa
Hideyuki Sakurai
Publication date
14-02-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 4/2024
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01901-z

Other articles of this Issue 4/2024

Annals of Nuclear Medicine 4/2024 Go to the issue

Original Article

Development and application of a fully automatic multi-function cassette module Mortenon M1 for radiopharmaceutical synthesis

Others

Nuclear medicine practice in Japan: a report of the ninth nationwide survey in 2022

Correction

Correction: Radiation dosimetry and pharmacokinetics of the tau PET tracer florzolotau (18F) in healthy Japanese subjects

Original Article

Left ventricular mechanical dyssynchrony after chemotherapy in breast cancer patients with normal rest gated SPECT-MPI

Original Article

Simultaneous evaluation of brain metastasis and thoracic cancer using semiconductor 11C-methionine PET/CT imaging

Original Article

Visual and whole-body quantitative analyses of 68 Ga-DOTATATE PET/CT for prognosis of outcome after PRRT with 177Lu-DOTATATE